(C) 2023 Electronic News Publishing, source
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,522 JPY | -0.20% | +2.08% | -9.70% |
05-01 | Malin Corp investee signs agreement with Astellas Pharma | AN |
05-01 | Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences | DJ |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,522 JPY | -0.20% | +2.08% | 17.24B | ||
27.18 USD | +6.09% | +3.46% | 145B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.70% | 17.24B | |
+33.25% | 704B | |
+28.59% | 577B | |
-3.55% | 348B | |
+18.16% | 327B | |
+4.36% | 288B | |
+14.81% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 147B |
- Stock Market
- Equities
- 4503 Stock
- News Astellas Pharma Inc.
- Astellas Pharma Inc. - XTANDI plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide